Congestive Heart Failure Drugs Market By Drug Class (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Beta Blockers, Diuretics, Aldosterone Antagonists, Vasodilators, Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Inotropic Agents, ARNI (Angiotensin Receptor-Neprilysin Inhibitors), Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• ACE Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Beta Blockers
• Diuretics
• Aldosterone Antagonists
• Vasodilators
• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
• Inotropic Agents
• ARNI (Angiotensin Receptor-Neprilysin Inhibitors)
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Novartis AG
• AstraZeneca
• Bristol Myers Squibb Company
• Merck & Co., Inc.
• Pfizer
• Amgen Inc.
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Bayer AG
• GSK plc
• Sanofi
• Boehringer Ingelheim International GmbH
• Abbott
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.